Vaccine biotechnology represents the application of advanced molecular and cellular techniques to develop, produce, and optimize vaccines. Traditional vaccine production often involved using weakened or inactivated forms of pathogens. In contrast, biotechnology allows for the creation of vaccines using specific genetic material, proteins, or subunits associated with the target pathogen. Recombinant DNA technology enables the insertion of genes encoding pathogenic proteins into host cells, such as yeast or bacteria, to produce large quantities of antigenic proteins for vaccine development. This approach enhances precision and safety in vaccine design. The advent of mRNA vaccine technology, exemplified by COVID-19 vaccines, represents a groundbreaking application of biotechnology. mRNA vaccines provide a platform for rapid response to emerging infectious diseases by delivering genetic instructions to cells, prompting them to produce viral proteins and induce an immune response. Biotechnological advancements also enable the development of subunit vaccines, virus-like particles, and vector-based vaccines. These approaches enhance the specificity, safety, and scalability of vaccine production, contributing to the development of novel vaccines against a wide range of infectious diseases. Ongoing research in vaccine biotechnology continues to revolutionize the field, offering innovative solutions for global health challenges.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States